3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Breast Neoplasms
3
Sarcoma, Endometrial Stromal
1
Perivascular Epithelioid Cell Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Breast Diseases
1
Brain Neoplasms
1
Brain Diseases
1
Advanced Breast Cancer
1
Adenosarcoma of the uterus
1
Interventions
Radiotherapy
3
Nivolumab
3
pembrolizumab
2
Temozolomide
2
Surveys and Questionnaires
2
Paclitaxel
2
ONC206
2
Magnetic Resonance Spectroscopy
2
Magnetic Resonance Imaging
2
Etoposide
2
Cyclophosphamide
2
Carboplatin
2
Biopsy
2
regorafenib
1
pegfilgrastim
1
mirdametinib
1
lutetium Lu 177 dotatate
1
fludarabine
1
etoposide phosphate
1
entrectinib
1
entinostat
1
elacestrant
1
decitabine and cedazuridine drug combination
1
cabozantinib
1
amino-acid, glucose, and electrolyte solution
1
alectinib
1
aflibercept
1
abemaciclib
1
Topotecan
1
Tissue Banks
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Central Nervous System Neoplasms
×
RAD1901
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled